Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.7491 USD
−118.51 M USD
20.97 M USD
45.77 M
About Cara Therapeutics, Inc.
Sector
Industry
CEO
Christopher A. Posner
Website
Headquarters
Stamford
Founded
2004
FIGI
BBG001J2QYS9
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CARA is 0.3100 USD — it has increased by 1.36% in the past 24 hours. Watch Cara Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cara Therapeutics, Inc. stocks are traded under the ticker CARA.
CARA stock has fallen by −7.85% compared to the previous week, the month change is a 15.05% rise, over the last year Cara Therapeutics, Inc. has showed a −70.19% decrease.
CARA reached its all-time high on Apr 9, 2021 with the price of 29.6473 USD, and its all-time low was 0.2400 USD and was reached on Jun 17, 2024. View more price dynamics on CARA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CARA stock is 5.00% volatile and has beta coefficient of 1.21. Track Cara Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cara Therapeutics, Inc. there?
Today Cara Therapeutics, Inc. has the market capitalization of 16.73 M, it has decreased by −6.90% over the last week.
Yes, you can track Cara Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Cara Therapeutics, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
CARA net income for the last quarter is −12.48 M USD, while the quarter before that showed −20.02 M USD of net income which accounts for 37.67% change. Track more Cara Therapeutics, Inc. financial stats to get the full picture.
No, CARA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 55.00 employees. See our rating of the largest employees — is Cara Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cara Therapeutics, Inc. EBITDA is −82.11 M USD, and current EBITDA margin is −578.20%. See more stats in Cara Therapeutics, Inc. financial statements.
Like other stocks, CARA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cara Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cara Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cara Therapeutics, Inc. stock shows the sell signal. See more of Cara Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.